<DOC>
	<DOCNO>NCT01235000</DOCNO>
	<brief_summary>Each winter , virus belong two kind influenza A ( `` A/H1N1 '' &amp; `` A/H3N2 '' ) two kind influenza B ( `` B/Yamagata '' &amp; `` B/Victoria '' ) cause illness . The yearly influenza vaccine design protect kind influenza A one kind influenza B . Current recommendation Canada eligible child less nine year age receive two dos influenza vaccine , child require single dose influenza vaccine subsequent year immunization . In previous study conduct early 2010 measure antibody response influenza B child previously receive two dos B/Yamagata kind virus contain 2008-09 influenza vaccine one dose B/Victoria kind virus contain 2009-10 recommended vaccine . The purpose follow-up study see protection ( antibody blood ) provide influenza B/Victoria kind virus 2009-10 vaccine improve another ( second ) dose B/Victoria kind virus include 2010-11 vaccine . Since influenza B illness especially child , understand best protect child kinds influenza B important .</brief_summary>
	<brief_title>TIV Infant/Toddler Response Evaluation - Follow-up Influenza B Boost</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Child previously participate TITRE II study ; Child healthy ( stable chronic condition acceptable ) establish health assessment interview verbal historydirected health examination ; Child available complete relevant procedure study period ; Parent legal guardian available reach phone study period ; Parent/guardian provide write informed consent ; And , parent/guardian fluent English/French . Child already receive 201011 seasonal ( TIV ) influenza vaccine Child receive immune globulin blood product within prior six week ; Child receive injected oral steroid within prior six week ; Child enrol clinical trial drug , vaccine medical device study period ; Or , child recently acquire health condition , opinion investigator , would interfere evaluation pose health risk child .</criteria>
	<gender>All</gender>
	<minimum_age>29 Months</minimum_age>
	<maximum_age>51 Months</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>Infant</keyword>
	<keyword>Dose-Response relationship , immunologic</keyword>
	<keyword>Prime-boost response</keyword>
</DOC>